Completed NA INTERVENTIONAL 1-arm NCT01157013

Role of Positron Emission Tomography in the Evaluation of Response to Sorafenib in Advanced Hepatocellular Carcinoma

The Role of Positron Emission Tomography (PET) Imaging in the Evaluation of Response to Sorafenib Treatment in Advanced Hepatocellular Carcinoma.

Sponsor: Aragon Health Science Institute

Conditions Hepatocellular Carcinoma

Interventions Positron emission tomography with fludeoxyglucose F 18

Updated 4 times since 2017 Last updated: Jul 2, 2010 Started: Jan 31, 2009 Primary completion: Jun 30, 2010 Completion: Jun 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Hepatocellular Carcinoma and is currently completed. Aragon Health Science Institute leads this study, which shows 4 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jan 2017 — Jan 2021 [monthly]

Completed NA

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aragon Health Science Institute
Carlos III Health Institute
Fondo de Investigacion Sanitaria
Hospital Miguel Servet
Spanish National Health System

Data source: Hospital Miguel Servet

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zaragoza, Spain